BioSpace News Archive

LumiraDx Limited announced that it has received notification from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450 for continued listing on the Nasdaq Global Market, since the closing bid price for the Company’s common shares on the Nasdaq Global Market was below US$1.00 for 30 consecutive trading days.

GeneDx Holdings Corp. announced the closing of its previously announced underwritten public offering of shares of its Class A common stock and concurrent registered direct offering of shares of its Class A common stock.

Dynavax Technologies Corporation announced that effective as of market open today, January 31, 2023, its common stock has been approved for uplisting to the Nasdaq Global Select Market® and will continue trading under its current ticker symbol “DVAX”.

Edwards Lifesciences reported financial results for the quarter ended December 31, 2022.

Varex Imaging Corporation announced its unaudited financial results for the first quarter of fiscal year 2023.

Prothena Corporation plc (NASDAQ:PRTA) today announced positive topline Phase 1 single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms

LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP test to aid in the diagnosis of CHF across Europe.

Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that management will present at the Guggenheim Healthcare Talks 2023 Oncology Day, being held February 8-9, 2023, in New York, NY.

Medexus Pharmaceuticals plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quarter ended December 31, 2022.

Evolent Health, Inc. (NYSE: EVH) today announced it will release its fourth quarter 2022 financial results on Wednesday, February 22, 2023 after market close, with a conference call to follow at 5:00 p.m. Eastern Time.